Fierce Healthcare March 11, 2021
Adaptive Biotechnologies launched a new diagnostic test for COVID-19 that uses machine learning technology from Microsoft to detect prior coronavirus infections.
The Food and Drug Administration (FDA) last week issued an emergency use authorization (EUA) for the biotech company’s T-cell-based test, called T-Detect COVID, which is the first screening to detect past COVID-19 infections using an individual’s T-cell profile.
Adaptive Biotechnologies‘ screening searches for T-cell responses against COVID-19 in the blood, rather than the immune proteins detected by conventional tests.
“People who have been unsure about a prior infection will now have another way to know if they had the virus,” said Chad Robins, CEO of Adaptive Biotechnologies, in a statement. “The authorization of T-Detect COVID represents a true breakthrough...
Today's Sponsors
Today's Sponsor